CatalystWireBeta

Conference attendance at Mello2026 Investor event

In brief · summary, not quotable

No summary for this filing – the full text is below.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes

LONDON and NEW YORK, 10 November 2026 – Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, announces that Renalytix will be presenting and exhibiting at the Mello2026 investor event on Tuesday 17 November, which will be held at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY.

James McCullough, CEO, will be presenting at 11:50am and 16:10pm on the day, providing an overview of the Company and strategy. A PDF copy of the presentation will be made available on the Company’s website at https://investors.renalytix.com/.

RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.

Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.

Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note